Phosphodiesterase 4: Rethinking cognition in Parkinson disease

The nosology and treatment options for cognitive impairment in Parkinson disease (PD) remains perhaps the greatest unmet clinical need.1 The reported frequency of mild cognitive impairment (MCI) in newly diagnosed PD has ranged from 22% to 43%.2,3 A proportion of those with PD-MCI progress to PD dementia (PDD), the prevalence of which is variously estimated between 24% and 31%, but is as high as 75% in longitudinal studies.4 Dementia is associated with increased disability, nursing home placement, mortality, and caregiver stress. Global cognition and executive/working memory deficits also occur in individuals at risk for PD.5 Which features of MCI are predictive of development of dementia remain a matter of debate.
Source: Neurology - Category: Neurology Authors: Tags: MRI, PET, Volumetric MRI, Parkinson's disease/Parkinsonism, Parkinson's disease with dementia EDITORIALS Source Type: research